Business Wire

QUIT-LIKE-SWEDEN

Share
Global Drive to ‘Quit Like Sweden’ Will Save Millions of Smokers’ Lives

INTERNATIONAL health experts today rallied behind a major new global effort to replicate Sweden’s success at eradicating smoking by embracing a comprehensive approach that could prevent many millions of premature deaths worldwide.

Quit Like Sweden (QLS), launched at a conference in Brasilia featuring medical professionals, politicians and policymakers, will motivate and support countries worldwide to emulate the triumph of Sweden, which is set to become the first nation to attain official ‘smoke-free’ status later this year.1

QLS founder Suely Castro, a Brazil-born harm reduction advocate, said: “Sweden has achieved this remarkable feat by ensuring that safer alternatives to smoking are accessible, acceptable and affordable.2

“A country where 49% of men used to smoke regularly has virtually wiped out this scourge by allowing its smokers to switch to products that pose just a fraction of the risks, such as snus [traditional smokeless tobacco] and other smoke-free alternatives like vapes and nicotine pouches.3

“Swedes are reaping the health dividend with significantly lower cancer cases and mortality rates compared to their European counterparts4. Now Quit Like Sweden will amplify this message globally, leveraging expertise and fostering collaboration across stakeholders to help countries replicate the Swedish Experience.”

Ms Castro was joined at the launch of her new platform by leading international harm reduction experts who unveiled new research showing that Brazil could save 1.36 million lives by 2060 by adopting the Swedish approach.5

Earlier research has shown that three million more Europeans would be alive today if other countries had implemented Sweden’s comprehensive approach to helping smokers quit.

Meanwhile, a study of low and middle-income countries (LMICs) shows that, through the adoption of Swedish-style policies, Kazakhstan could prevent 165 000 premature deaths in the next four decades, while South Africa, Bangladesh and Pakistan could save 320 000, 920 000, and 1 200 000 lives, respectively.6

Research co-author Dr Anders Milton, a former chair of the World Medical Association and former Secretary General of the Swedish Medical Association, said: “Sweden is winning the war against smoking with a comprehensive approach to tobacco control that supplements traditional cessation and preventive measures with an all-important added element: giving smokers the opportunity to switch to safer alternatives.

“It has set out a policy roadmap that should be treated as a gift to global public health and, potentially, one of the greatest ever breakthroughs in tackling non-communicable diseases (NCDs).

”That’s why QLS is so important. By spreading the message of the Swedish Experience to all corners, many millions of premature deaths - including almost 1.4 million here in Brazil - could be prevented in the next four decades.”

London-based Ms Castro said she had been motivated to launch QLS by her father, a lifelong smoker who lives in Bahia.

“Like Brazil’s other 22 million smokers, my father has been deprived of the lifelines given to the Swedes because of regulatory barriers and societal resistance towards alternative nicotine products.

“Quit Like Sweden aims to empower individuals - here in Brazil, and around the globe - to reclaim control over their health.”

-ENDS-

Notes to editors:

Quit Like Sweden is a platform for people who want to eradicate smoking. The smoking rate in Sweden, where once 49% of the male population smoked regularly, is about to fall below 5%, the level regarded by the World Health Organization as officially ‘smoke-free’. Quit Like Sweden aims to encourage other countries to replicate the Swedish Experience by using traditional cessation and prevention measures while making alternatives to smoking accessible, acceptable and affordable.

An official launch of Quit Like Sweden in Brasilia on April 10 features eminent guest speakers on a variety of topics:

Public policy: Swedish MP Jesper Skalberg Karlsson, Brazilian Senator Soraya Thronicke and Federico Fernandez, We Are Innovation.

Misinformation and the impact on consumers: Miguel Okumura, THR Brasil and Alexandro Lucian, DIRETA.

The Swedish Experience’s life-saving potential for Brazil: Dr Delon Human, Dr Anders Milton and Prof. Dr. Erika Magalhaes Suzigan.

Public health policymaking: Dr Roberto Sussman, Dr Konstantinos Farsalinos, Dr Christopher Russell, David Sweanor, Dr Marewa Glover, Jorge A. Costa e Silva.

1 https://smokefreesweden.org/wp-content/themes/smokefreesweden/assets/pdf/reports/Report%20The%20Swedish%20Experience%20EN.pdf
2 https://www.rcplondon.ac.uk/file/3563/download
3 https://www.ucl.ac.uk/news/2019/oct/e-cigarettes-may-help-over-50000-smokers-quit-england-each-year
4 https://www.researchgate.net/publication/345643346_Tobacco-related_mortality_SwedenEU_easier_readable_charts
5 per co-authored by Dr Delon Human, Dr Anders Milton & Dr Erica Suzigan, 2024.
6 https://smokefreesweden.org/lives-saved.pdf

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410373868/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment2.12.2025 14:30:00 CET | Press release

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers. Innovativ

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 14:00:00 CET | Press release

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become

AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 14:00:00 CET | Press release

Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will evaluate 160 MBq and 200 MBq doses of ADVC001 using a randomized, multi-dose-response design and adaptive dosing strategies to optimize clinical outcomes across three indications: metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) in pre-chemotherapy and post-177Lu-PSMA radioligand therapy (RLT) settings AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling

Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 14:00:00 CET | Press release

Establishment of the London office follows Luma AI’s $900 million Series C investment led by HUMAIN - marking the company’s first major step towards international scale with plans to deepen partnerships across the UK, European Union, and Saudi Arabia in the first phase of expansion.Former Monks and WPP executive Jason Day was appointed Head of EMEA to launch Luma AI internationally and drive worldwide growth across creative, advertising, gaming, and entertainment sectors.Luma AI plans to add 200 new jobs in London in 2026. Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING

Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 13:30:00 CET | Press release

Eventbrite stockholders to receive $4.50 per share in cash Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after cl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye